Metformin Inhibits N-Methyl-N-Nitrosourea Induced Gastric Tumorigenesis in db/db Mice

Abstract

Aim

Type 2 diabetes can elevate risk of gastric cancer and metformin, an anti-diabetic agent, has an inhibitory effect against gastric cancer cell in vitro. However, the effect of metformin on type 2 diabetes-related gastric tumorigenesis in vivo is still not clear. In the present study, we aim to detect whether metformin can inhibit increased risk of gastric cancer in diabetic db/db mice and which the potential anti-cancer mechanisms of metformin are.

Methods

4-week-old mice were divided into 3 groups (2 db/db mice groups and one wild type mice group). All diabetic and non-diabetic mice were treated with N-Methyl-N-Nitrosourea (MNU) for 20 weeks to induce gastric tumorigenesis. At week 21, one db/db mice group were treated with metformin (5 mg/ml) for 10 weeks and the other 2 groups were treated with saline. Blood samples were collected for testing insulin and insulin-like growth factor (IGF)-1. Stomach tissues were collected for histopathological evaluation and mRNAs analysis.

Results

Metformin significantly decreased incidence of MNU-induced gastric dysplasia and cancer in diabetic db/db mice. Furthermore, metformin reduced serum insulin as well as IGF-1, and also suppressed expression of insulin receptor, IGF-1, IGF-1 receptor and several pro-inflammatory cytokines mRNAs in stomach of db/db mice, but did not significantly influence IGF-2 and IGF-2 receptor expressions.

Conclusions

The results show that metformin can prevent the risk of gastric cancer in type 2 diabetes and the protective mechanisms may involve in an inhibitory effect of metformin on insulin as well as IGF-1 signals and cancer related pro-inflammatory cytokines.

Key words

diabetes - gastric cancer - metformin - insulin

^* contribute equally

• References

• 1 Sekikawa A, Fukui H, Maruo T. et al. Diabetes mellitus increases the risk of early gastric cancer development. Eur J Cancer 2014; 50: 2065-2071
• 2 Tian T, Zhang LQ, Ma XH. et al. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes 2012; 120: 217-223
• 3 Sen S, He Y, Koya D. et al. Cancer biology in diabetes. J Diabetes Investig 2014; 5: 251-264
• 4 Hidaka A, Sasazuki S, Goto A. et al. Plasma insulin, C-peptide and blood glucose and the risk of gastric cancer: the Japan Public Health Center-based prospective study. Int J Cancer 2015; 136: 1402-1410
• 5 Marimuthu SP, Vijayaragavan P, Moysich KB. et al. Diabetes mellitus and gastric carcinoma: Is there an association?. J Carcinog 2011; 10: 30
• 6 Giovannucci E, Harlan DM, Archer MC. et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685
• 7 Kim YI, Kim SY, Cho SJ. et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther 2014; 39: 854-863
• 8 Chae YK, Arya A, Malecek MK et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;
• 9 Bowker SL, Majumdar SR, Veugelers P. et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258
• 10 Algire C, Zakikhani M, Blouin MJ. et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008; 15: 833-839
• 11 Coban S. Does long-term metformin usage reduce gastric cancer risk?. Turk J Gastroenterol 2014; 25: 125
• 12 Yoshizawa N, Yamaguchi H, Yamamoto M. et al. Gastric carcinogenesis by N-Methyl-N-nitrosourea is enhanced in db/db diabetic mice. Cancer Sci 2009; 100: 1180-1185
• 13 Ohno T, Shimizu M, Shirakami Y. et al. Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice. PLoS One 2015; 10: e124081
• 14 Saxena A, Shoeb M, Tammali R. et al. Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Cancer Lett 2014; 355: 141-147
• 15 Han G, Gong H, Wang Y. et al. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 2015; 16: 77-87
• 16 Kato K, Gong J, Iwama H. et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11: 549-560
• 17 Zhao Z, Cheng X, Wang Y. et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One 2014; 9: e95884
• 18 Chen G, Feng W, Zhang S. et al. Metformin inhibits gastric cancer via the inhibition of HIF1alpha/PKM2 signaling. Am J Cancer Res 2015; 5: 1423-1434
• 19 Hayakawa Y, Hirata Y, Nakagawa H. et al. Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. Proc Natl Acad Sci USA 2011; 108: 780-785
• 20 Kwon HJ, Won YS, Nam KT. et al. Vitamin D(3) upregulated protein 1 deficiency promotes N-methyl-N-nitrosourea and Helicobacter pylori-induced gastric carcinogenesis in mice. Gut 2012; 61: 53-63
• 21 Quinn BJ, Dallos M, Kitagawa H. et al. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) 2013; 6: 801-810
• 22 Yamachika T, Nakanishi H, Inada K. et al. N-methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. Jpn J Cancer Res 1998; 89: 385-391
• 23 Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002; 51: 130-131
• 24 Suo WH, Zhang N, Wu PP. et al. Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer. Br J Pharmacol 2012; 165: 135-147
• 25 Tajima K, Nakamura A, Shirakawa J. et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. Am J Physiol Endocrinol Metab 2013; 305: E987-E998
• 26 Giovannucci E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 2001; 131S: 3109S-3120S
• 27 Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18: R125-R147
• 28 Cusi K, Maezono K, Osman A. et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-320
• 29 Frasca F, Pandini G, Sciacca L. et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114: 23-37
• 30 Dowling RJ, Niraula S, Chang MC. et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast cancer research: BCR 2015; 17: 540
• 31 Ben SI, Laurent K, Giuliano S. et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465-2475
• 32 Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res 2011; 19: 275-285
• 33 Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169
• 34 Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr-Relat Cancer 2012; 19: R225-R241
• 35 Gryko M, Kisluk J, Cepowicz D. et al. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol 2014; 65: 135-140
• 36 Yi HK, Hwang PH, Yang DH. et al. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001; 37: 2257-2263
• 37 Abdel-Rahman O. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. Med Oncol 2015; 32: 431
• 38 Karnevi E, Said K, Andersson R. et al. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. Bmc Cancer 2013; 13: 235
• 39 Pavelic K, Kolak T, Kapitanovic S. et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 2003; 201: 430-438
• 40 Francisco CO, Catai AM, Moura-Tonello SC. et al. Cytokine profile and lymphocyte subsets in type 2 diabetes. Braz J Med Biol Res 2016; 49: e5062
• 41 Tsujimoto H, Ono S, Ichikura T. et al. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?. Gastric Cancer 2010; 13: 212-221
• 42 Zhou F, Cheng L, Qiu LX et al. Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. Oncotarget. 2016;
• 43 Zhao G, Zhu G, Huang Y. et al. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. Oncol Rep 2016; 35: 1787-1795
• 44 Sun Z, Meng Y, Liu G. et al. Effect of interleukin-1beta and tumor necrosis factor alpha gene silencing on mouse gastric cancer cell proliferation and migration. Oncol Lett 2016; 11: 2559-2565
• 45 Kang JS, Bae SY, Kim HR. et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis 2009; 30: 1987-1996